Novartis/GSK mega-deal to prompt copycat dealmaking?
This article was originally published in Scrip
It's not something you wake up to every day. After a relatively quiet holiday weekend with only rumors of a Pfizer/AstraZeneca mega-merger to liven things up (scripintelligence.com, 21 April 2014), Novartis and GlaxoSmithKline (and Eli Lilly) announced a deal that had everyone rubbing their eyes and taking a closer look (scripintelligence.com, 22 April 2014). In the words of GSK's CEO Sir Andrew Witty: "We needed the planets to align, and that's what's happened here."